The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells

Itaru Matsumura, Yuzuru Kanakura, Takashi Kato, Hirokazu Ikeda, Yoko Horikawa, Jun Ishikawa, Hitoshi Kitayama, Tetsuo Nishiura, Yoshiaki Tomiyama, Hiroshi Miyazaki, Yuji Matsuzawa

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Thrombopoietin (TPO) is implicated as a primary regulator of megakaryopoiesis and thrombopoiesis. However, the biologic effects of TPO on human acute myeloblastic leukemia (AML) cells are largely unknown. To determine if recombinant human (rh) TPO has proliferation-supporting and differentiation-inducing activities in AML cells, 15 cases of AML cells that were exclusively composed of undifferentiated leukemia cells and showed growth response to rhTPO in a short-term culture (72 hours) were subjected to long-term suspension culture with or without rhTPO. Of 15 cases, rhTPO supported proliferation of AML cells for 2 to 4 weeks in 4 cases whose French-American-British subtypes were M0, M2, M4, and M7, respectively. In addition to the proliferation-supporting activity, rhTPO was found to induce AML cells to progress to some degree of megakaryocytic differentiation at both morphologic and surface-phenotypic levels in 2 AML cases with M0 and M7 subtypes. The treatment of AML cells with rhTPO resulted in rapid tyrosine phosphorylation of the TPO-receptor, c-mpl, and STAT3 in all of cases tested. By contrast, the expression of erythroid/megakaryocyte-specific transcription factors (GATA-1, GATA-2, and NF-E2) was markedly induced or enhanced in only 2 AML cases that showed megakaryocytic differentiation in response to rhTPO. These results suggested that, at least in a fraction of AML cases, TPO could not only support the proliferation of AML cells irrespective of AML subtypes, but could also induce megakaryocytic differentiation, possibly through activation of GATA-1, GATA-2, and NF-E2.

Original languageEnglish
Pages (from-to)3074-3082
Number of pages9
JournalBlood
Volume88
Issue number8
Publication statusPublished - 1996 Oct 15
Externally publishedYes

Fingerprint

Thrombopoietin
Acute Myeloid Leukemia
Thrombopoietin Receptors
GATA Transcription Factors
Phosphorylation
Tyrosine
Suspensions
Chemical activation
Thrombopoiesis
Megakaryocytes
Leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Matsumura, I., Kanakura, Y., Kato, T., Ikeda, H., Horikawa, Y., Ishikawa, J., ... Matsuzawa, Y. (1996). The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood, 88(8), 3074-3082.

The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. / Matsumura, Itaru; Kanakura, Yuzuru; Kato, Takashi; Ikeda, Hirokazu; Horikawa, Yoko; Ishikawa, Jun; Kitayama, Hitoshi; Nishiura, Tetsuo; Tomiyama, Yoshiaki; Miyazaki, Hiroshi; Matsuzawa, Yuji.

In: Blood, Vol. 88, No. 8, 15.10.1996, p. 3074-3082.

Research output: Contribution to journalArticle

Matsumura, I, Kanakura, Y, Kato, T, Ikeda, H, Horikawa, Y, Ishikawa, J, Kitayama, H, Nishiura, T, Tomiyama, Y, Miyazaki, H & Matsuzawa, Y 1996, 'The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells', Blood, vol. 88, no. 8, pp. 3074-3082.
Matsumura, Itaru ; Kanakura, Yuzuru ; Kato, Takashi ; Ikeda, Hirokazu ; Horikawa, Yoko ; Ishikawa, Jun ; Kitayama, Hitoshi ; Nishiura, Tetsuo ; Tomiyama, Yoshiaki ; Miyazaki, Hiroshi ; Matsuzawa, Yuji. / The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. In: Blood. 1996 ; Vol. 88, No. 8. pp. 3074-3082.
@article{8e80ec49c69d4c33b442eb419df459a9,
title = "The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells",
abstract = "Thrombopoietin (TPO) is implicated as a primary regulator of megakaryopoiesis and thrombopoiesis. However, the biologic effects of TPO on human acute myeloblastic leukemia (AML) cells are largely unknown. To determine if recombinant human (rh) TPO has proliferation-supporting and differentiation-inducing activities in AML cells, 15 cases of AML cells that were exclusively composed of undifferentiated leukemia cells and showed growth response to rhTPO in a short-term culture (72 hours) were subjected to long-term suspension culture with or without rhTPO. Of 15 cases, rhTPO supported proliferation of AML cells for 2 to 4 weeks in 4 cases whose French-American-British subtypes were M0, M2, M4, and M7, respectively. In addition to the proliferation-supporting activity, rhTPO was found to induce AML cells to progress to some degree of megakaryocytic differentiation at both morphologic and surface-phenotypic levels in 2 AML cases with M0 and M7 subtypes. The treatment of AML cells with rhTPO resulted in rapid tyrosine phosphorylation of the TPO-receptor, c-mpl, and STAT3 in all of cases tested. By contrast, the expression of erythroid/megakaryocyte-specific transcription factors (GATA-1, GATA-2, and NF-E2) was markedly induced or enhanced in only 2 AML cases that showed megakaryocytic differentiation in response to rhTPO. These results suggested that, at least in a fraction of AML cases, TPO could not only support the proliferation of AML cells irrespective of AML subtypes, but could also induce megakaryocytic differentiation, possibly through activation of GATA-1, GATA-2, and NF-E2.",
author = "Itaru Matsumura and Yuzuru Kanakura and Takashi Kato and Hirokazu Ikeda and Yoko Horikawa and Jun Ishikawa and Hitoshi Kitayama and Tetsuo Nishiura and Yoshiaki Tomiyama and Hiroshi Miyazaki and Yuji Matsuzawa",
year = "1996",
month = "10",
day = "15",
language = "English",
volume = "88",
pages = "3074--3082",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells

AU - Matsumura, Itaru

AU - Kanakura, Yuzuru

AU - Kato, Takashi

AU - Ikeda, Hirokazu

AU - Horikawa, Yoko

AU - Ishikawa, Jun

AU - Kitayama, Hitoshi

AU - Nishiura, Tetsuo

AU - Tomiyama, Yoshiaki

AU - Miyazaki, Hiroshi

AU - Matsuzawa, Yuji

PY - 1996/10/15

Y1 - 1996/10/15

N2 - Thrombopoietin (TPO) is implicated as a primary regulator of megakaryopoiesis and thrombopoiesis. However, the biologic effects of TPO on human acute myeloblastic leukemia (AML) cells are largely unknown. To determine if recombinant human (rh) TPO has proliferation-supporting and differentiation-inducing activities in AML cells, 15 cases of AML cells that were exclusively composed of undifferentiated leukemia cells and showed growth response to rhTPO in a short-term culture (72 hours) were subjected to long-term suspension culture with or without rhTPO. Of 15 cases, rhTPO supported proliferation of AML cells for 2 to 4 weeks in 4 cases whose French-American-British subtypes were M0, M2, M4, and M7, respectively. In addition to the proliferation-supporting activity, rhTPO was found to induce AML cells to progress to some degree of megakaryocytic differentiation at both morphologic and surface-phenotypic levels in 2 AML cases with M0 and M7 subtypes. The treatment of AML cells with rhTPO resulted in rapid tyrosine phosphorylation of the TPO-receptor, c-mpl, and STAT3 in all of cases tested. By contrast, the expression of erythroid/megakaryocyte-specific transcription factors (GATA-1, GATA-2, and NF-E2) was markedly induced or enhanced in only 2 AML cases that showed megakaryocytic differentiation in response to rhTPO. These results suggested that, at least in a fraction of AML cases, TPO could not only support the proliferation of AML cells irrespective of AML subtypes, but could also induce megakaryocytic differentiation, possibly through activation of GATA-1, GATA-2, and NF-E2.

AB - Thrombopoietin (TPO) is implicated as a primary regulator of megakaryopoiesis and thrombopoiesis. However, the biologic effects of TPO on human acute myeloblastic leukemia (AML) cells are largely unknown. To determine if recombinant human (rh) TPO has proliferation-supporting and differentiation-inducing activities in AML cells, 15 cases of AML cells that were exclusively composed of undifferentiated leukemia cells and showed growth response to rhTPO in a short-term culture (72 hours) were subjected to long-term suspension culture with or without rhTPO. Of 15 cases, rhTPO supported proliferation of AML cells for 2 to 4 weeks in 4 cases whose French-American-British subtypes were M0, M2, M4, and M7, respectively. In addition to the proliferation-supporting activity, rhTPO was found to induce AML cells to progress to some degree of megakaryocytic differentiation at both morphologic and surface-phenotypic levels in 2 AML cases with M0 and M7 subtypes. The treatment of AML cells with rhTPO resulted in rapid tyrosine phosphorylation of the TPO-receptor, c-mpl, and STAT3 in all of cases tested. By contrast, the expression of erythroid/megakaryocyte-specific transcription factors (GATA-1, GATA-2, and NF-E2) was markedly induced or enhanced in only 2 AML cases that showed megakaryocytic differentiation in response to rhTPO. These results suggested that, at least in a fraction of AML cases, TPO could not only support the proliferation of AML cells irrespective of AML subtypes, but could also induce megakaryocytic differentiation, possibly through activation of GATA-1, GATA-2, and NF-E2.

UR - http://www.scopus.com/inward/record.url?scp=10244231042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244231042&partnerID=8YFLogxK

M3 - Article

C2 - 8874206

AN - SCOPUS:10244231042

VL - 88

SP - 3074

EP - 3082

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -